Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study
- 1 December 2018
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 40 (12) , 2077-2087
Abstract
No abstract availableKeywords
Funding Information
- Biogen
- Genzyme
- Mallinckrodt
- Novartis
- Biogen
- Genentech,
- GlaxoSmithKline
- MedImmune
- Novartis
- Roche
- Sanofi-Genzyme
- Sun Pharma
This publication has 17 references indexed in Scilit:
- Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient settingInternational Journal of Clinical and Health Psychology, 2015
- Efficacy of delayed‐release dimethyl fumarate in relapsing‐remitting multiple sclerosis: integrated analysis of the phase 3 trialsAnnals of Clinical and Translational Neurology, 2014
- Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM StudiesClinical Therapeutics, 2014
- Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisMultiple Sclerosis and Related Disorders, 2014
- Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM studyMultiple Sclerosis Journal, 2013
- Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: The DEFINE studyMultiple Sclerosis Journal, 2013
- Treatment Patterns in Disease-Modifying Therapy for Patients With Multiple Sclerosis in the United StatesClinical Therapeutics, 2013
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple SclerosisNew England Journal of Medicine, 2012
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple SclerosisNew England Journal of Medicine, 2012
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993